Article
Immunology
Shizhao Yang, Zhaohao Huang, Xiuxing Liu, He Li, Lihui Xie, Xiaoqing Chen, Feng Wen, Dan Liang, Wenru Su
Summary: The study compared the effectiveness of adalimumab plus conventional therapy versus conventional therapy alone in treating patients with retinal vasculitis due to refractory Behcet's uveitis. Results showed that adalimumab plus conventional therapy outperformed conventional therapy alone in improving inflammatory parameters, reducing relapse time, and tapering daily glucocorticoid doses. Adverse events were mainly upper respiratory tract infection and gastrointestinal discomfort in the adalimumab group, while fewer adverse events were observed in the conventional therapy group.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Immunology
Ruixia Li, Xiaofei Li, He Zhou, Yanting Shi, Fang Wang, Tong Wu, Jie Liang
Summary: This case report describes a 50-year-old female patient with intestinal BD who had a positive response to anti-TNF-alpha biologics but not to conventional drugs. After treatment with VDZ, the patient showed significant improvement in abdominal pain and joint pain, and complete healing of intestinal mucosal ulcers. However, oral and vulvar ulcers required the addition of thalidomide for resolution.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Ophthalmology
Masoud Soheilian, Nazanin Ebrahimiadib, Alireza Hedayatfar, Maryam Hosseini, Mohammad Zarei, Nassim Anjidani
Summary: The study demonstrated that biosimilar adalimumab (CinnoRA (R)) is effective and well-tolerated in patients with Behcet's uveitis, improving visual acuity, reducing vitreous haze, and improving anterior chamber cell grade, with a corticosteroid-sparing effect.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Pharmacology & Pharmacy
Shizhao Yang, Zhaohao Huang, Yunwei Hu, Jian Zhang, Xiuxing Liu, He Li, Lihui Xie, Feng Wen, Dan Liang, Wenru Su
Summary: The study compared the efficacy of ADA with conventional therapy in treating retinal vasculitis in initial treatment of Behcet's Uveitis patients. The results showed significant improvements in patients in the ADA group, with fewer relapses, longer remission periods, better BCVA improvement, inflammation control, and lower glucocorticoid dosages compared to the conventional therapy group.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Tianyu Tao, Shizhao Yang, Daquan He, Zhaohuai Li, Binyao Chen, Lei Zhu, Wenru Su
Summary: This cross-sectional study investigated the efficacy and safety of dexamethasone implant, Ozurdex(R), as an adjunctive treatment for refractory Behcet's uveitis (BU). The study included 61 patients (80 eyes) divided into non-DEX and DEX groups. After >12 months of treatment, the DEX group showed significantly higher improvement in fluorescein angiography score and vitritis score compared to the non-DEX group. Despite worsening posterior capsule opacification score, the DEX group had higher usage of low-dose systemic glucocorticoid and fewer relapse times. Therefore, Ozurdex(R) is an effective and safe option for refractory BU patients, providing control of vasculitis, stabilization of vitreous inflammation, prevention of recurrence, and reduction of daily glucocorticoid doses.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Xiao-Wen Huang, Huan-Xin Zheng, Meng-Lei Wang, Wan-Mei He, Mei-Xin Feng, Kang Zeng, Li Li
Summary: This retrospective study describes the successful use of the anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy and provides clinical evidence of its ability to improve skin lesions and relieve pain.
Article
Medicine, General & Internal
Wenyan Zhou, Tian Liu, Xian Xiao, Jing He
Summary: This report presents a case of refractory Behçet's disease treated with low-dose IL-2. The treatment was successful and the patient remained symptom-free for a significant period of time. This suggests that low-dose IL-2 is a safe and effective treatment for refractory Behçet's disease.
Article
Immunology
Matheus Vieira, Solene Buffier, Mathieu Vautier, Alexandre Le Joncour, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurence Bouillet, Estibaliz Lazaro, Stephane Barete, Laurent Misery, Delphine Gobert, Tiphaine Goulenok, Olivier Fain, Karim Sacre, Pascal Seve, Patrice Cacoub, Cloe Comarmond, David Saadoun
Summary: The study demonstrates the long-term safety and effectiveness of apremilast for refractory joint disease in Behcet's syndrome, with 65% of patients achieving complete response in joint symptoms at month 6. However, discontinuation rates were significantly higher than reported in clinical trials.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Erkan Alpsoy, Pietro Leccese, Giacomo Emmi, Shigeaki Ohno
Summary: Behcet's disease is a chronic, inflammatory multisystem disease with a wide range of symptoms affecting various organs. Early diagnosis, personalized treatment, and multidisciplinary collaboration are crucial in reducing the incidence and mortality of the disease.
FRONTIERS IN MEDICINE
(2021)
Article
Ophthalmology
Jurgen Sota, Stefano Gentileschi, Maria Orsetta Perfetti, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani
Summary: The study demonstrates the significant efficacy of SB5 in treating Behcet's syndrome-related uveitis, showing its ability to control inflammation relapses, resolve retinal vasculitis, and preserve visual acuity.
OPHTHALMOLOGY AND THERAPY
(2021)
Review
Immunology
Suibin Lin, Zhirong Xu, Zhiming Lin, Baozhao Xie, Junmei Feng
Summary: Behcet's disease is a chronic multi-systemic disease characterized by oral ulcers, genital ulcers, ocular inflammatory involvements, and other systemic features. Ocular involvements are common and can cause severe tissue damage and potential blindness. The pathogenesis of the disease is not fully understood, but genetic factors, environmental triggers, and immunological abnormalities play important roles. Novel biotherapies targeting specific proteins have shown promise in recent years. This review focuses on ocular involvement, mechanisms, and advances in therapeutic approaches, particularly novel biologics. Management during pregnancy is also discussed.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Chuanbin Tang, Yu Song, Xiaofan Huang, Yuanming Li, Yisilamujiang Tuerxun, Xingjian Hu, Huadong Li, Long Wu
Summary: Behcet's disease is a rare inflammatory disease that affects multiple systems and can cause aortic regurgitation. Due to the unique pathogenesis of the disease, there is a low preoperative diagnosis rate and a high risk of complications after surgery, resulting in poor prognosis for patients with severe aortic regurgitation in Behcet's disease.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Rheumatology
T. B. van der Houwen, P. M. van Hagen, J. A. M. van Laar
Summary: Behcet's disease is an auto-inflammatory disease characterized by recurrent painful mucocutaneous ulcerations. The pathogenesis involves genetic susceptibility, microbial triggers, and dysregulated immune responses. Treatment focuses on controlling inflammation and managing organ involvement based on individual characteristics.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Multidisciplinary Sciences
Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D'Inca, Edoardo Vincenzo Savarino
Summary: The study analyzed data from IBD patients who switched to ABP501 and SB5, showing stable clinical and biochemical responses. While 8 patients in the ABP501 group needed to add steroids after 6 months, a significant decrease in CRP levels was observed in the SB5 group. Some patients stopped therapy after 6 months.
SCIENTIFIC REPORTS
(2021)
Article
Ophthalmology
Bo Hee Kim, Un Chul Park, Sung Wook Park, Hyeong Gon Yu
Summary: The study found that UWFA scores significantly improved in Behcet's uveitis patients treated with adalimumab, and further improvement of UWFA scores was observed even in patients with clinically quiescent inflammation.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Ophthalmology
Lucia Miguel-Escuder, Amanda Garcia Tirado, Maria Sainz-de-la-Maza, Gerard Espinosa, Aina Moll-Udina, Victor Llorenc, Alba Parrado-Carrillo, Alfredo Adan
Summary: This study retrospectively describes three cases of Anti-TNF-alpha-induced lupus (ATIL) in patients with non-infectious uveitis (NIU), who developed antinuclear antibody (ANA) and anti-dsDNA antibody positivity, arthritis, and in one case, skin lesions under adalimumab treatment. The condition resolved in all patients after adalimumab withdrawal, with one patient requiring corticosteroids, two patients requiring non-steroidal anti-inflammatory drugs, and one patient requiring hydroxychloroquine. None of the patients required another immunosuppressive drug. Two patients were able to continue follow-up without anti-TNF-alpha therapy, while the remaining patient switched to another anti-TNF-alpha treatment (golimumab). A review of the literature and comparison with previous ATIL cases was also conducted.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Rheumatology
Ana Matas-Garcia, Alfredo Guillen-Del-Castillo, Boris Kisluk, Albert Selva-O'Callaghan, Gerard Espinosa, Sergio Prieto-Gonzalez, Pedro Moreno Lozano, Gloria Garrabou, Josep Maria Grau-Junyent, Carmen Pilar Simeon-Aznar, Jose C. Milisenda
Summary: This study analyzed the clinico-serological and histological phenotypes of SSc patients with associated myopathy. The patients were divided into two subgroups based on histological findings: fibrosing and inflammatory. Significant differences were found in clinical data, antibody profile, electrophysiologic studies, treatment response, mortality, and survival between the two groups.
Article
Rheumatology
G. Pires da Rosa, E. Ferreira, B. Sousa-Pinto, P. Bettencourt, G. Espinosa, R. Cervera
Summary: This study analyzed a cohort of patients with laboratory criteria for anti-phospholipid syndrome (APS) but only presenting "non-criteria" clinical manifestations. The patients were compared with definite APS patients. The results showed that these "clinical non-criteria" patients had mainly hematological and neurological involvements, with significant treatment use. Some patients may progress to future systemic lupus erythematosus (SLE).
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Giuseppe Barilaro, Carlo Della Rocca, Alexandra Esteves, Ricard Cervera, Gerard Espinosa
Summary: This study analyzed the association between the average 'adjusted' Global APS Score (aGAPSS) and the change in Damage Index for APS (DIAPS) in patients with thrombotic and non-thrombotic APS. The results showed that a higher average aGAPSS value was associated with an increase in DIAPS during follow-up, suggesting that the average aGAPSS score can predict the increase in DIAPS.
Article
Rheumatology
Laura Pelegrin, Montse Morato, Olga Araujo, Marc Figueras-Roca, Javier Zarranz-Ventura, Alfredo Adan, Ricard Cervera, Ricardo P. Casaroli-Marano, Vanesa Budi, Lucia Barrera-Lopez, Jose Rios, Jose Hernandez-Rodriguez, Gerard Espinosa
Summary: This study detected preclinical changes in retinal microvascularization and retinal and optical nerve structure in SLE patients using optical coherence tomography. The results showed that structural and perifoveal vascular parameters were decreased in SLE patients, especially in those with longer disease duration and higher disease damage. APS was associated with preclinical damage to the optic nerve and impairment of the perifoveal microvasculature.
Article
Rheumatology
Mohamed-Yacine Khitri, Alessandra Bartoli, Georgina Maalouf, Alban Deroux, Carlo Salvarani, Giacomo Emmi, Omer Karadag, Gerard Espinosa, Mathilde Leclercq, Gabriele Simonini, Mathieu Vautier, Patrice Cacoub, David Saadoun
Summary: This study evaluated the efficacy of tocilizumab in patients with refractory Behcet disease. The results showed that 83% of patients responded to tocilizumab, with 60% achieving complete response and 23% achieving partial response. Tocilizumab also significantly reduced steroid dosage and the need for concomitant disease-modifying antirheumatic drugs. However, a small number of patients experienced mild to moderate side effects and serious adverse events.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Medicine, General & Internal
Isaac Pons, Joana Louro, Marta Sitges, Barbara Vidal, Ricard Cervera, Gerard Espinosa
Summary: This study describes the prevalence, clinical and laboratory features, and evolution of heart valve involvement in patients with APS. The results showed that 50% of APS patients had valve involvement, with most of them being female and having arterial hypertension and arterial thrombosis. The valve involvement group had a higher mortality rate.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Albert Perez-Isidro, Marc Xipell, Arturo Llobell, Noemi De Moner, Gema M. Lledo, Ricard Cervera, Sergio Prieto-Gonzalez, Luis F. Quintana, Gerard Espinosa, Mila Garcia-Ormaechea, Estibaliz Ruiz-Ortiz, Odette Vinas
Summary: This study investigated whether dsDNA antibody-secreting B-cells could be a complementary biomarker for monitoring disease activity and prognosis in SLE patients. The results showed that SLE-ELISpot had the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and increased risk of disease flare-up, especially renal flare. Combining hypocomplementemia and high SLE-ELISpot results further increased these risks. Therefore, adding SLE-ELISpot to the current follow-up protocol can improve clinicians' personalized care decisions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Jose Manuel Mascaro, Ignasi Rodriguez-Pinto, Gabriela Poza, Anna Mensa-Vilaro, Julian Fernandez-Martin, Luis Caminal-Montero, Gerard Espinosa, Jose Hernandez-Rodriguez, Marina Diaz, Joana Rita-Marques, Raimon Sanmarti, Santos Castaneda, Dolores Colunga, Ruben Coto-Hernandez, Patricia Fanlo, Jose Ignacio Elejalde, Segundo Bujan, Ignasi Figueras, Francisco Manuel Marco, Mariano Andres, Silvia Suarez, Andres Gonzalez-Garcia, Xavier Fusta-Novell, Clara Garcia-Belando, Ana Granados, Maria Teresa Fernandez-Figueras, Neus Quilis, Maria Orriols-Caba, Ricardo Gomez de la Torre, Maria Cinta Cid, Georgina Espigol-Frigole, Alba Alvarez-Abella, Eztizen Labrador, Maria Rozman, Monica Lopez-Guerra, Paola Castillo, Jose R. Alamo-Moreno, Eva Gonzalez-Roca, Susana Plaza, Virginia Fabregat, Rocio Lara, Esther F. Vicente-Rabaneda, Sonia Tejedor-Vaquero, Giuliana Magri, Nuria Bonet, Manuel Solis-Moruno, Andrea Cerutti, Oscar Fornas, Ferran Casals, Jordi Yague, Juan Arostegui
Summary: Thirty patients with adult-onset autoinflammatory diseases were definitively diagnosed with VEXAS syndrome through genetic analyses. Patients presented with late-onset disease and symptoms including cutaneous lesions, fever, pulmonary manifestations, and arthritis. The UBA1 variants were detected in both hematopoietic and non-hematopoietic tissues.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Dermatology
Bianca Bergamini, Julien Seneschal, Kristin J. Meyers, Frederick Durand, Ewa Haladyj, Gerard Espinosa, Jacob P. Thyssen
Summary: A total of 117 pregnancies with exposure to baricitinib were analyzed, and the clinical outcomes were found to be comparable to other targeted therapies for immune-mediated diseases or general population.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Rheumatology
Gerard Espinosa, Ricard Cervera
Review
Medicine, General & Internal
Adriana Pane, Camila Milad, Marta Santana-Dominguez, Nuria Banos, Cristina Borras-Novell, Gerard Espinosa, Laura Magnano, Meritxell Nomdedeu, Pedro Juan Moreno-Lozano, Frederic Cofan, Merce Placeres, Rosa Maria Fernandez, Judit Garcia-Villoria, Gloria Garrabou, Irene Vinagre, Laura M. Tanner, Cristina Montserrat-Carbonell, Maria de Tallo Forga-Visa
Summary: Lysinuric protein intolerance (LPI) is a rare metabolic disorder that presents challenges during pregnancy and delivery. This case report highlights the successful natural birth of a woman with LPI, despite various challenges and risks. Collaboration between interdisciplinary teams and careful consideration of risks are crucial in achieving a successful pregnancy and delivery.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Health Care Sciences & Services
Ivan Contreras, Judith Navarro-Otano, Ignasi Rodriguez-Pinto, Amparo Gueemes, Eduarda Alves, Roberto Rios-Garces, Gerard Espinosa, Aida Alejaldre, Aleix Beneyto, Charrise Mary Ramkissoon, Josep Vehi, Ricard Cervera
Summary: This study explores the relationship between the autonomic nervous system and inflammatory pathways in systemic lupus erythematosus patients. The aim is to improve patient outcomes by treating autonomic nervous system dysregulation with noninvasive vagus nerve stimulation. Data on biomarkers, physiological signals, patient outcomes, and quality of life are being collected and analyzed. The results of this study will contribute to the development of patient-tailored vagus nerve stimulation therapies and improve the quality of life for systemic lupus erythematosus patients.
JMIR RESEARCH PROTOCOLS
(2023)